Blood cancer sits at the center of this dementia and brain health question.
A targeted drug called pemigatinib is producing remarkable results for patients with a rare and aggressive blood cancer that has historically been a death sentence without a bone marrow transplant. In the Phase 2 FIGHT-203 trial, led by Stanford Medicine researchers and published in August 2025, nearly 75% of patients with myeloid/lymphoid neoplasms harboring FGFR1 rearrangements saw their cancers become undetectable after treatment with pemigatinib — a disease that otherwise carries a one-year overall survival rate of just 43%. For the many patients too sick or too frail to undergo the grueling process of a stem cell transplant, this drug is not just an alternative; it is a bridge that makes transplant possible for some and a standalone treatment for others.
This matters to anyone following brain health and aging because blood cancers disproportionately affect older adults, and the cognitive toll of aggressive treatments like bone marrow transplants — including chemotherapy-related cognitive decline, prolonged hospitalization, and the neurological complications of graft-versus-host disease — is well documented. Treatments that reduce that burden have real implications for preserving quality of life and cognitive function. Beyond pemigatinib, this article covers a newly discovered drug resistance mechanism in myelofibrosis, the broader shift away from bone marrow transplants toward CAR-T cell therapy, and what all of this means for patients and families navigating blood cancer treatment decisions.
Table of Contents
- Why Can’t Some Blood Cancer Patients Get a Bone Marrow Transplant?
- How Pemigatinib Works Against a Cancer With a 43% Survival Rate
- The Hidden Resistance Problem in Myelofibrosis
- CAR-T Therapy vs. Bone Marrow Transplant — Weighing the Tradeoffs
- Cognitive and Neurological Risks Across Blood Cancer Treatments
- What Genomic Testing Means for Treatment Decisions
- Where Blood Cancer Treatment Is Headed
- Conclusion
- Frequently Asked Questions
Why Can’t Some Blood Cancer Patients Get a Bone Marrow Transplant?
The only established cure for myeloid/lymphoid neoplasms with FGFR1 rearrangements is a hematopoietic stem cell transplant — what most people know as a bone marrow transplant. But “cure” is a misleading word when many patients never get the chance to attempt it. The transplant process requires intensive pretreatment with high-dose chemotherapy or radiation to destroy the existing bone marrow, and the patient must be healthy enough to survive that onslaught. Older patients, those with organ damage from prior treatments, or people with other serious health conditions frequently fail to qualify. Then there is graft-versus-host disease, a potentially fatal complication where the donor’s immune cells attack the recipient’s body, which makes the procedure a serious gamble even for those who do qualify.
Pemigatinib, marketed as Pemazyre and manufactured by Incyte Corporation, changes this equation. The drug works by interfering with FGFR1 activity — the abnormally active fibroblast growth factor receptor 1 that drives these cancers. By shrinking the disease to undetectable levels, pemigatinib can bring patients into a condition where they become eligible for transplant. In the FIGHT-203 trial, 13 out of 45 participants went on to receive potentially curative stem cell transplants after pemigatinib treatment. For the remaining patients who still could not undergo transplant, the drug produced responses lasting months to years, offering meaningful time that this disease has never previously allowed.
How Pemigatinib Works Against a Cancer With a 43% Survival Rate
FGFR1-rearranged myeloid/lymphoid neoplasms are driven by a specific genetic mutation that causes the fibroblast growth factor receptor 1 to become permanently switched on, sending constant growth signals to cancer cells. Pemigatinib is a selective FGFR inhibitor — it blocks this receptor with precision, cutting off the signal that tells the cancer to keep growing. The FIGHT-203 trial, a multicenter international Phase 2 study, demonstrated that this targeted approach could push the disease into complete remission in the majority of patients, a result that led to FDA approval. However, targeted therapy is not without its own complications.
Patients on FGFR inhibitors can experience hyperphosphatemia (dangerously elevated phosphorus levels), vision disturbances, fatigue, and gastrointestinal side effects. These are generally more manageable than the toxicities of a full transplant regimen, but they require careful monitoring. It is also important to understand that pemigatinib is specifically approved for patients with confirmed FGFR1 rearrangements — genomic testing is essential before treatment, and the drug will not work for blood cancers driven by other mutations. If your oncologist has not discussed molecular profiling, that conversation should happen early.
The Hidden Resistance Problem in Myelofibrosis
While pemigatinib addresses one type of rare blood cancer, researchers at MetroHealth and Case Western Reserve University announced a separate breakthrough in 2026 that tackles a different but equally frustrating problem: drug resistance in myelofibrosis. Myelofibrosis is a bone marrow cancer where scar tissue replaces healthy marrow, and the standard treatment involves JAK2 inhibitor drugs. These medications help patients feel better — reducing spleen enlargement, easing symptoms — but they do not cure the disease and often stop working over time as the cancer finds ways around them. The MetroHealth team discovered why.
They identified a hidden “survival axis” — a backup pathway called NFκB/IL-6/JAK2/STAT — that keeps cancer cells alive even when JAK2 inhibitors are active. Think of it as a cancer cell’s emergency generator kicking on when you cut the main power line. Using ixazomib, a drug already FDA-approved for other blood cancers, or emetine, the researchers were able to shut down this backup engine in laboratory studies. This discovery could lead to clinical trials combining ixazomib or emetine with existing JAK2 inhibitors, potentially transforming a disease that currently has no reliable long-term drug treatment.
CAR-T Therapy vs. Bone Marrow Transplant — Weighing the Tradeoffs
The story of pemigatinib fits into a much larger shift in how blood cancers are treated. According to STAT News reporting from December 2024, bone marrow transplants are becoming less common for blood cancer as newer options — particularly CAR-T cell therapy — gain ground. Six commercial CAR-T products are now FDA-approved, covering relapsed or refractory non-Hodgkin lymphoma, multiple myeloma, and both adult and pediatric relapsed B-cell acute lymphoblastic leukemia. In non-Hodgkin lymphoma, CAR-T is already offered as second-line therapy, which has sharply reduced the number of autologous transplants performed.
The advantages of CAR-T over transplant are real: lower toxicities, no strict age limits, and effectiveness in patients with chemotherapy-resistant, high-risk diseases that have already failed transplant. But the comparison is not straightforward. Allogeneic transplants — those using a donor’s cells rather than the patient’s own — have actually been growing at 7 to 8 percent per year, fueled by the expansion of mismatched and unrelated donor transplants. CAR-T also carries its own serious risks, including cytokine release syndrome and neurotoxicity, the latter of which is particularly relevant for anyone concerned about brain health. The CARTITUDE-6 study, run by the European Myeloma Network, is currently comparing cilta-cel CAR-T cell therapy directly against autologous stem cell transplant in newly diagnosed myeloma, with enrollment planned to finish by 2026 — a trial that may definitively answer which approach is better for certain patients.
Cognitive and Neurological Risks Across Blood Cancer Treatments
For readers of a brain health website, the neurological side effects of blood cancer treatments deserve direct attention. Bone marrow transplants are associated with “chemo brain” — the cognitive fog, memory problems, and difficulty concentrating that can persist for months or years after treatment. The intensive conditioning regimens damage not only cancer cells but also healthy brain tissue, and graft-versus-host disease can cause inflammation that crosses the blood-brain barrier. Prolonged hospitalization and isolation during transplant recovery also contribute to cognitive decline, particularly in older adults already at risk for dementia.
CAR-T therapy introduces a different but overlapping set of neurological concerns. Immune effector cell-associated neurotoxicity syndrome, or ICANS, occurs in a significant percentage of CAR-T recipients and can range from mild confusion and word-finding difficulties to seizures and cerebral edema. While most cases resolve, the long-term cognitive effects of CAR-T are still being studied. Targeted therapies like pemigatinib generally have a lighter neurological footprint, but any cancer treatment that involves prolonged illness, fatigue, and disruption of normal life carries a risk of cognitive consequences — especially in patients over 65, where the line between treatment-related impairment and early neurodegenerative disease can be difficult to draw.
What Genomic Testing Means for Treatment Decisions
The success of pemigatinib underscores a principle that is reshaping all of cancer medicine: treatment is increasingly dictated by the specific genetic mutations driving a patient’s disease, not just the organ or tissue where the cancer appears. For patients diagnosed with a myeloid or lymphoid neoplasm, genomic profiling — often through next-generation sequencing panels — can reveal whether an FGFR1 rearrangement is present and whether a drug like pemigatinib is appropriate.
Similarly, the MetroHealth discovery about the NFκB/IL-6/JAK2/STAT survival axis in myelofibrosis suggests that future treatment decisions may depend on identifying which resistance pathways are active in a given patient. Families navigating a blood cancer diagnosis should ask oncologists explicitly about molecular testing, as it can mean the difference between a standard protocol and access to a targeted therapy that may work far better.
Where Blood Cancer Treatment Is Headed
The convergence of targeted drugs, CAR-T cell therapy, and a growing understanding of resistance mechanisms points toward a future where bone marrow transplant, long the backbone of blood cancer treatment, becomes one option among many rather than the default. The FIGHT-203 trial showed that a well-designed targeted therapy can make transplant possible for patients who were previously too sick, while potentially sparing others from needing it at all.
The MetroHealth discovery about myelofibrosis resistance may open clinical trials that fundamentally change how a currently incurable disease is managed. And the ongoing CARTITUDE-6 study will provide head-to-head data comparing CAR-T against transplant in myeloma — evidence that could reshape treatment guidelines within the next few years. For patients and caregivers, the practical takeaway is that the treatment landscape is shifting fast, and decisions made today should account for options that may not have existed even a year ago.
Conclusion
Blood cancer treatment is in the middle of a genuine transformation. Pemigatinib has given patients with FGFR1-rearranged myeloid/lymphoid neoplasms a real chance at remission — and in many cases, a bridge to the curative transplant they could not previously access. Meanwhile, the discovery of hidden resistance pathways in myelofibrosis and the rapid expansion of CAR-T cell therapy are challenging the long-standing dominance of bone marrow transplant as the primary treatment for blood cancers.
For anyone concerned about brain health, these developments carry a secondary but important message: treatments that reduce the need for high-dose chemotherapy and prolonged hospitalization are treatments that may better protect cognitive function. As genomic testing becomes standard, as targeted therapies multiply, and as clinical trials like CARTITUDE-6 deliver results, patients and families will have more — and potentially less damaging — options than ever before. The key is to stay informed, ask about molecular profiling early, and work with oncology teams who are tracking these advances in real time.
Frequently Asked Questions
What is pemigatinib and what does it treat?
Pemigatinib (brand name Pemazyre) is an FDA-approved targeted drug made by Incyte Corporation that treats previously treated myeloid/lymphoid neoplasms with FGFR1 rearrangements — a rare and aggressive blood cancer. It works by blocking the abnormally active fibroblast growth factor receptor 1. In the Phase 2 FIGHT-203 trial, nearly 75% of patients achieved undetectable cancer levels.
Can pemigatinib replace a bone marrow transplant?
Not exactly. A stem cell transplant remains the only established cure for FGFR1-rearranged blood cancers. However, pemigatinib can shrink the disease enough to make patients eligible for transplant who previously were not, and it provides meaningful, lasting responses for patients who cannot undergo transplant at all.
What is the new discovery about myelofibrosis drug resistance?
Researchers at MetroHealth and Case Western Reserve University found that myelofibrosis cancer cells use a backup survival pathway (NFκB/IL-6/JAK2/STAT) to keep growing even when JAK2 inhibitor drugs are active. Drugs like ixazomib and emetine were able to shut down this backup pathway in research settings, which could lead to new clinical trials.
Is CAR-T therapy better than a bone marrow transplant?
It depends on the cancer type, patient health, and individual circumstances. CAR-T offers lower toxicities and no strict age limits, and it works in some patients whose cancers resisted chemotherapy or failed transplant. However, CAR-T carries its own risks, including neurotoxicity. The CARTITUDE-6 study is currently comparing CAR-T against transplant in myeloma to help answer this question definitively.
Do blood cancer treatments affect cognitive health?
Yes. Bone marrow transplants are associated with chemo brain and cognitive decline from intensive conditioning regimens and potential graft-versus-host disease. CAR-T therapy can cause neurotoxicity syndrome. Targeted therapies like pemigatinib generally have fewer neurological side effects, though any prolonged illness and treatment can affect cognition, particularly in older adults.
You Might Also Like
- The Rosacea Drug Working When Antibiotics Don’t
- This Glaucoma Drug Has Been Used for 50 Years — Here’s Why
- The Smoking Cessation Drug That Has a Dark Side — Chantix Warning
For more, see NIH MedlinePlus — cognitive testing.
